Dear fellow shareholders, When I joined Emergent in February 2024, we embarked on a multi-year plan to stabilize, turnaround, and ultimately transform our business. I am proud to say our stabilization phase was completed this past fall, ahead of schedule, thanks to the dedication and commitment of our entire team. Our strategic stabilization plan included strengthening the balance sheet and substantially reducing debt to allow for focused, profitable growth around business lines built to compete in today’s competitive landscape. Additionally, we implemented a leaner, more flexible organization by streamlining our manufacturing network, including several asset divestitures. With these actions behind us, I believe Emergent has a strong foundation, momentum, and freedom to operate through our turnaround, the next phase of our multi-year plan. In 2024, several important product milestones were successfully achieved, including: • FDA approval of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) for the prevention of mpox disease in individuals determined to be at high risk for mpox infection as the public health outbreak hits Africa and other regions. • Secured a number of U.S. government contracts for our medical countermeasures business, reinforcing the longstanding partnership between Emergent and the U.S. government to meet the country’s preparedness needs. • Distributed 11 million cartons (includes 2 doses) of NARCAN® Nasal Spray 4 mg to customers and patients across the U.S. and Canada. • Roughly one year after NARCAN® Nasal Spray became the first FDA-approved over-the-counter naloxone nasal spray, the CDC reported the first annual decrease of opioid overdose deaths since 2018.1 • Opened a new West Coast distribution center as part of our best-in-class NARCANDirect™ distribution network, deepening our value proposition for public interest customers. • Implemented actions to further broaden over-the-counter access of NARCAN® Nasal Spray through retailers, public places, businesses, and workplaces. Our products play a direct role in helping communities prepare for today’s health challenges and tomorrow’s threats. Emergent’s 2024 results and outlook for 2025 demonstrate our ability to adapt and evolve our business, take on new challenges, and innovate to address future urgent health crises. We remain optimistic in our future and aspire to be the leader in solving public health threats for communities around the world as we carry out our mission to protect and save lives. We look forward to a strong 2025 and beyond. JOE PAPA President and CEO 1 Centers for Disease Control and Prevention. U.S. Overdose Deaths Decrease in 2023, First Time Since 2018. May 15, 2024. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2024/20240515.htm. Accessed September 26, 2024. WE’RE PREPARING FOR TOMORROW BY TRANSFORMING OUR COMPANY TODAY
EXECUTIVE OFFICERS BOARD OF DIRECTORS CORPORATE HEADQUARTERS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM INVESTOR RELATIONS STOCK TRANSFER AGENT AND REGISTRAR ANNUAL MEETING MARKET INFORMATION CORPORATE GOVERNANCE Investors with questions concerning account information, new certificate issuances, lost or stolen certificate replacement, securities transfers, or the processing of a change of address should contact: . Our chief executive officer intends to submit his annual chief executive officer certification to the New York Stock Exchange within 30 days of the date of our Annual Meeting of Stockholders in accordance with the New York Stock Exchange listing requirements. Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. Our Board of Directors has adopted Corporate Governance Guidelines, along with the charters of the Board Committees and a Code of Conduct and Business Ethics for directors, officers and employees, all of which are available on the company’s website at www.emergentbiosolutions.com. Additional copies of the company’s Form 10-K for the year ended December 31, 2024 of the exhibits thereto, are available without charge upon written request to Investor Relations, Emergent BioSolutions Inc., 300 Professional Drive, Gaithersburg, MD 20879, or by calling (240) 631-3200, or accessing the company's website at www.emergentbiosolutions.com. Broadridge Corporate Issuer Solutions, Inc. *All titles are as of 3/21/2025 Joseph Papa President, CEO and Director Richard Lindahl Executive Vice President, Chief Financial Officer and Treasurer Coleen Glessner Executive Vice President, Quality and Ethics and Compliance Jessica Perl Senior Vice President, General Counsel and Corporate Secretary William Hartzel Senior Vice President, Manufacturing and Bioservices Paul Williams Senior Vice President, Products Business Simon Lowry Senior Vice President, Chief Medical Officer, Head of Research and Development Stephanie Duatschek Senior Vice President and Chief Strategy and Transformation Officer Michelle Pepin Senior Vice President and Chief Human Resources Officer Zsolt Harsanyi, Ph.D. Independent Director, Chairman of the Board Former Chief Executive Officer and Chairman of the Board, Exponential Biotherapies Inc. Audit and Finance Committee Member Quality, Compliance, Manufacturing and Risk Management Committee Member Scientific Review Committee Member Neal Fowler Independent Director Chief Executive Officer of Pathalys Pharma, Inc. Audit and Finance Committee Member Scientific Review Committee Member Louis W. Sullivan, M.D. Independent Director President Emeritus, Morehouse School of Medicine; Former Secretary, Department of Health and Human Services Chair, Compensation Committee Nominating and Corporate Governance Committee Member Sujata Dayal Independent Director Former Vice President and Global Chief Compliance Officer, Medline Industries, Inc. Chair, Quality, Compliance, Manufacturing and Risk Management Committee Special Transactions Committee Member Keith Katkin Independent Director Former Chief Executive Officer, Urovant Sciences Ltd. Chair, Special Transactions Committee Compensation Committee Member Nominating and Corporate Governance Committee Member Marvin White Independent Director President and Chief Executive Officer, Aptevo Therapeutics Inc. Chair, Audit and Finance Committee Scientific Review Committee Member Special Transactions Committee Member Donald DeGolyer Independent Director Founder, and Former Chief Executive Officer and Director of Vertice Pharma (a Warburg Pincus company) Compensation Committee Member Special Transactions Committee Member Ronald B. Richard Independent Director Former President and Chief Executive Officer, The Cleveland Foundation Chair, Nominating and Corporate Governance Committee Compensation Committee Member Kathryn C. Zoon, Ph.D. Independent Director Scientist Emeritus, National Institute of Allergy and Infectious Diseases at the National Institutes of Health Chair, Scientific Review Committee Nominating and Corporate Governance Committee Member Quality, Compliance, Manufacturing and Risk Management Committee Member 300 Professional Drive Gaithersburg, MD 20879 Tel: 240-631-3200 Fax: 240-631-3203 Ernst & Young LLP, McLean, VA, United States P.O. Box 1342 Brentwood, NY 11717 1-877-830-4936 or 1-720-378-5591 Shareholder@broadridge.com Richard Lindahl Executive Vice President, Chief Financial Officer (240) 631-3360 Lindahlr@ebsi.com Emergent BioSolutions Inc.’s common stock trades on the New York Stock Exchange under the trading symbol "EBS." The annual meeting of Emergent BioSolutions Inc. will be held in virtual format via live audio webcast on April 30, 2025 at 9:00 a.m. Eastern Time. Stockholders can attend the meeting online at www.virtualshareholdermeeting.com/EBS2025
